Previous 10 | Next 10 |
DUBLIN, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the second quarter fiscal year 2023 on Tuesday, October 3, 2023. The ...
2023-09-12 06:56:57 ET Nasdaq has notified that Trinity Biotech ( NASDAQ: TRIB ) that the Company is not in compliance with Nasdaq listing rule, as the minimum bid price of the Company’s American depositary shares has been below US $1.00 per share for 30 consecutive busines...
DUBLIN, Ireland, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Premier Resolution System, an automated analyzer for the accurate & precise quantification of hemoglobins F and A2, and the detection of >200 hem...
2023-07-06 13:08:25 ET Gainers: EdtechX Holdings Acquisition ( EDTX ) +40% . Mullen Automotive ( MULN ) +35% . Genius Sports Limited ( GENI ) +21% . Incannex Healthcare Limited ( IXHL ) +19% . Sweetgreen ( SG ) +18% . urban-g...
2023-07-06 10:14:27 ET Trinity Biotech press release ( NASDAQ: TRIB ): Q1 GAAP ADS of -$0.152. Revenue of $14.83M (-5.4% Y/Y). For further details see: Trinity Biotech GAAP ADS of -$0.152, revenue of $14.83M
DUBLIN, Ireland, July 06, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced the Company’s results for the quarter ended March 31, 2023. Summ...
2023-07-05 17:35:50 ET Trinity Biotech ( NASDAQ: TRIB ) is scheduled to announce Q1 earnings results on Thursday, July 6th, after market close. The consensus EPS Estimate is -$0.06 (+99.9% Y/Y) and the consensus Revenue Estimate is $18.5M (-1.5% Y/Y). Over the last 2 y...
DUBLIN, July 03, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the first quarter fiscal year 2023 on Thursday, July 6, 2023. The Comp...
DUBLIN, Ireland, May 05, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a leading developer and manufacturer of diagnostic solutions for the point-of-care and clinical laboratory markets, today reported the receipt of a formal notification from The Nasd...
DUBLIN, Ireland, April 27, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a leading developer and manufacturer of diagnostic solutions for the point-of-care and clinical laboratory markets, today announced that it has closed the recently announced sale ...
News, Short Squeeze, Breakout and More Instantly...
DUBLIN, June 24, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced steps to advance its next generation continuous glucose monitoring (...
DUBLIN, June 10, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, announces that its senior management team plans to at...
DUBLIN, June 03, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the launch of its continuous glucose monitoring (“CGM”...